Acceleron Pharma (NASDAQ: XLRN) July call option implied volatility is at 62, August is at 56; compared to its 52-week range of 37 to 152 into announcing with its partner Celgene (CELG) positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia.